Background and Study Aims Thyroid-associated orbitopathy, the most common extrathyroidal manifestation of Graves’ disease, is an autoimmune inflammation of orbital soft tissue. We report the study assessing the effect of immunosuppressive treatment with methylprednisolone on selected antioxidant parameters in patients with Graves’ disease with active thyroid-associated orbitopathy. Patients and Methods Activity and serum levels of selected antioxidant parameters as well as lipid peroxidation products were determined in a group of 56 patients with active thyroid-associated orbitopathy at three time-points: at baseline, after the discontinuation of intravenous methylprednisolone treatment and at 3 months after the discontinuation of additional oral methylprednisolone treatment. A control group consisted of 20 healthy age- and sex-matched volunteers. Results We found an increased activity of superoxide dismutase and glutathione peroxidase and increased serum levels of uric acid, malondialdehyde and conjugated dienes, as well as a reduced activity of paraoxonase-1 and reduced serum vitamin C level in the study group at baseline. Systemic intravenous and oral methylprednisolone therapy led to normalization of activity and concentration of the most studied parameters. Conclusion Results of our study confirmed that oxidative stress is one of the factors involved in the pathogenesis of thyroid-associated orbitopathy and the methyloprednisolone treatment is effective in reducing both clinical symptoms and oxidative stress in patients with this disease.

中文翻译：

---

免疫抑制对患有活动性甲状腺相关眼眶病的格雷夫斯病患者选择的抗氧化参数的影响

背景和研究目的 甲状腺相关眼眶病是 Graves 病最常见的甲状腺外表现，是眼眶软组织的自身免疫性炎症。我们报告了一项研究，该研究评估了甲基强的松龙免疫抑制治疗对患有活动性甲状腺相关眼眶病的格雷夫斯病患者所选抗氧化参数的影响。患者和方法 在三个时间点测定一组 56 名活动性甲状腺相关眼眶病患者的活性和血清中选定的抗氧化参数以及脂质过氧化产物水平：基线时、静脉注射甲基强的松龙治疗后和 3在停止额外的口服甲基强的松龙治疗后数月。对照组由 20 名年龄和性别匹配的健康志愿者组成。结果 我们发现基线研究组的超氧化物歧化酶和谷胱甘肽过氧化物酶活性增加，血清尿酸、丙二醛和共轭二烯水平升高，对氧磷酶-1 活性降低，血清维生素 C 水平降低。全身性静脉内和口服甲基强的松龙治疗导致活动和研究最多的参数浓度正常化。结论 我们的研究结果证实，氧化应激是甲状腺相关眼眶病发病机制中涉及的因素之一，甲泼尼龙治疗可有效减轻该病患者的临床症状和氧化应激。丙二醛和共轭二烯，以及基线时研究组对氧磷酶 1 活性降低和血清维生素 C 水平降低。全身性静脉内和口服甲基强的松龙治疗导致活动和研究最多的参数浓度正常化。结论 我们的研究结果证实，氧化应激是甲状腺相关眼眶病发病机制中涉及的因素之一，甲泼尼龙治疗可有效减轻该病患者的临床症状和氧化应激。丙二醛和共轭二烯，以及基线时研究组对氧磷酶 1 活性降低和血清维生素 C 水平降低。全身性静脉内和口服甲基强的松龙治疗导致活动和研究最多的参数浓度正常化。结论 我们的研究结果证实，氧化应激是甲状腺相关眼眶病发病机制中涉及的因素之一，甲泼尼龙治疗可有效减轻该病患者的临床症状和氧化应激。